ICHNOS GLENMARK INNOVATION (IGI) ANNOUNCES IND SUBMISSION TO U.S. FDA FOR ISB 2301, A FIRST-IN-CLASS MULTISPECIFIC IMMUNE CELL ACTIVATOR TARGETING SOLID TUMORS

Reuters · 19h ago

Please log in to view news